| |
|
|
|
Cymabay Therapeutics  
|
|
5.88 0.16 (0.03%) |
01-22 16:00 |
|
Open: |
5.7 |
Pre close: |
5.72 |
Target:
|
7.85
|
|
High: |
5.89 |
Low: |
5.64 |
Resistance:
|
6.72
7.40
|
|
Volume: |
636,581 |
Market Cap: |
405M |
Support:
|
5.62
4.68
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
5.87
 |
MACD |
MACD(12,26):
|
-0.27  |
|
MA(20): |
6.06 |
Signal(12,26,9): |
-0.28 |
|
MA(100): |
7.09 |
Stochastic Oscillator |
%K(14,3):
|
14.17 |
|
MA(250): |
4.66 |
%D(3): |
17.86 |
|
Average Volume(K) |
3-Month: |
102483
|
52-Week |
High:
|
9.06 |
|
10-Days: |
86439 |
Low: |
1.21 |
|
RSI |
RSI(14):
|
39.77 |
Change(%): |
209.5 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.940 |
Return on Equity (ttm) |
-35.0 |
Shares Out. (M) |
68.89 |
|
EPS Est. Current Year |
-0.820 |
Return on Assets (ttm) |
-19.6 |
Shares Float (M) |
50.35 |
|
EPS Est. Next Year |
-0.740 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.40 |
|
EPS Est. Next Quarter |
-0.160 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
84.85 |
|
Forward EPS |
-1.530 |
Gross Profit (p.s.) |
-0.937 |
Shares Short (K) |
4080 |
|
Book Value (p.s.) |
2.270 |
EBITDA (p.s.) |
-0.904 |
P/E |
-6.26 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
2.59 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-58.05 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-32.90 |
P/CF |
-6.98 |
|
|
|
|
|
|
